ArticleInternational journal of clinical and experimental pathology2018
IgG4+ plasma cell infiltration is correlated with the development of inflammatory bowel disease and can be regulated by TLR-4.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 7 citations in OpenAlex.
- Membranous nephropathy secondary to very early-onset inflammatory bowel disease in a 3-year-old boy: case report.CEN case reports · 2026Article
- B cell-driven immune remodeling in inflammatory bowel disease: links to pathogenesis and therapeutic failure.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Article
- Crohn's Disease-Like Features in a Patient With IgE and Selective IgG1 and IgG3 Deficiency.Cureus · 2023Article
- Pancreatic Disorders in Patients with Inflammatory Bowel Disease.Digestive diseases and sciences · 2022Review
- TAK-242 ameliorates DSS-induced colitis by regulating the gut microbiota and the JAK2/STAT3 signaling pathway.Microbial cell factories · 2020Article
- Association of serum IgG4 and disease outcomes in patients with inflammatory bowel disease.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin 4 (IgG4) is commonly considered a hallmark of autoimmune pancreatitis (AIP). Inflammatory bowel disease (IBD) is believed to play a substantial role in the setting of AIP. Toll-like receptor 4 (TLR4) plays an important role in inflammation. The relationship between IgG4 and TLR4 in the process of IBD is incompletely explored. Our study aimed to assess the expression of IgG4 and TLR4 in IBD patients and to find the role of IgG4 and TLR4 in the IBD process. A cohort of 68 IBD patients was enrolled in our study, and 20 healthy persons served as a control group. Intestinal IgG4 positive (IgG4+) plasma cell infiltration was measured by immunohistochemistry. Serum IgG4 and TLR4 levels were measured by ELISA. Fifteen additional features from the patients' general medical information and lab data were also collected to assess the risk factors of IBD activity by logistical analysis. BALB/c mice were used to build a rat IBD model with dextran sulfate sodium (DSS). The TLR4 inhibitor TAK242 was used to regulate the expression of TLR4. The expression of IgG4 and TLR4 in serum was detected by ELISA. The expression of IgG4 and TLR4 in the intestines were assayed with western blot. Our results revealed that the infiltration of IgG4+ plasma cells was higher in IBD patients (14/68 vs 0/20, P<0.05). The incidence of IgG4+ plasma cells in the IBD group (48.5%) was higher than in the control group (33/68 vs 0/20, P<0.05). Serum IgG4 and TLR4 levels in the IBD group were significantly higher compared with the control group (P<0.05). Based on our logistical analysis, three variables: IgG4+ plasma cell infiltration, CRP, and HB were identified as independent risk factors with odds ratios of 10.917, 1.031, and 0.923, respectively (
Indexed as
Identifiers
31949851PMC6962960W3007311271What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.